INTRODUCTION {#s1}
============

It is widely accepted that lipid metabolism plays an essential role in the pathogenesis of atherosclerosis, a major cause for coronary heart disease (CHD) \[[@R1], [@R2]\]. The past decade has witnessed substantial advances in understanding the genetic basis of lipid abnormalities of biomedical importance. In particular, cholesteryl ester transfer protein (CETP) is a plasma glycoprotein involved in lipid metabolism, and it can trigger the transfer of cholesteryl esters from high-density lipoprotein (HDL) to apolipoprotein B-containing lipoproteins in exchange for triglycerides, a key step known as 'reverse cholesterol transport' \[[@R3]\]. The gene encoding CETP is shipped with 2056 polymorphic loci ( <https://www.ncbi.nlm.nih.gov/gene/1071>), and some of them have been proposed as potential regulators of CETP deficiency and HDL cholesterol (HDL-C) increase, as indicated by a comprehensive meta-analysis of 92 published studies \[[@R4]\]. However, the exact mechanism whereby *CETP* genetic loci alter susceptibility to CHD remains largely unknown. A clear understanding of how *CETP* genetic loci regulate lipid metabolism associated with CHD is therefore a challengeable task. To take a step further, we in this study meta-analytically evaluated the association of a promoter functional polymorphism, C-629A (rs1800775) in *CETP* with CHD risk and lipid changes. This polymorphism was reported to be a Sp1/Sp3 transcription factor binding site that can regulate the transcriptional activity of human *CETP* promoter \[[@R5], [@R6]\].

RESULTS {#s2}
=======

Eligible articles {#s2_1}
-----------------

Figure [1](#F1){ref-type="fig"} is a flow diagram that depicted the steps of filtrating articles for this meta-analysis. From 459 initially identified articles from 4 electronic databases, 17 that satisfied our eligibility criteria were finally analyzed \[[@R7]--[@R24]\]. There were 12 qualified articles including 16 study groups (5441 CHD patients and 7967 controls) for the association between *CETP* C-629A polymorphism and CHD risk \[[@R7]--[@R18]\]. There were 10 qualified articles including 20 study groups (22488 subjects) for the relationship between *CETP* C-629A polymorphism and circulating lipid changes \[[@R13], [@R15]--[@R17], [@R19]--[@R24]\].

![Flow diagram depicting the steps of article selection for this meta-analysis](oncotarget-08-2153-g001){#F1}

Study characteristics {#s2_2}
---------------------

Table [1 (A, B, C)](#T1){ref-type="table"} summarizes the characteristics of all study groups, and [Supplementary Table S1](#SD2){ref-type="supplementary-material"} provides the mean values of lipid concentrations under study across C-629A genotypes. For the genotype-disease association, 7 of 16 study groups were based on East Asians, 3 on Caucasians, 2 on Middle Easterns and 4 on mixed populations. Coronary stenosis was assessed in 9 study groups and myocardial infarction in 7 study groups. Ten study groups enrolled controls from general populations and 6 from hospitals. Twelve studies were in retrospective designs and 4 in prospective designs. Age was reported to be matched between CHD patients and controls by 11 studies (Table [1](#T1){ref-type="table"}).

###### The baseline characteristics of all eligible articles for the genotype-disease association

  Author (year)                   Ethnicity        CHD subtype             Source       Design          Matched   Genotyping   Patients   Controls
  ------------------------------- ---------------- ----------------------- ------------ --------------- --------- ------------ ---------- ----------
  Eiriksdottir G (2001)           Caucasian        Myocardial infarction   Population   Prospective     NR        RFLP         388        794
  Freeman DJ (2003)               Caucasian        Myocardial infarction   Population   Prospective     YES       Non-RFLP     498        1108
  Tobin MD (2004)                 Caucasian        Myocardial infarction   Hospital     Retrospective   NA        Non-RFLP     547        505
  Zheng K (2005)                  Asian            Coronary stenosis       Hospital     Retrospective   YES       Non-RFLP     203        209
  Zee RY (UK) (2006)              Mixed            Myocardial infarction   Population   Prospective     YES       Non-RFLP     547        505
  Zee RY (PHS) (2006)             Mixed            Myocardial infarction   Population   Prospective     YES       Non-RFLP     523        2092
  Meiner V (males) (2008)         Mixed            Myocardial infarction   Population   Retrospective   YES       Non-RFLP     321        308
  Meiner V (females) (2008)       Mixed            Myocardial infarction   Population   Retrospective   YES       Non-RFLP     256        351
  Tanrikulu S (2009)              Middle Eastern   Coronary stenosis       Hospital     Retrospective   YES       RFLP         120        120
  Poduri A (2009)                 Asian            Coronary stenosis       Population   Retrospective   YES       RFLP         265        150
  Padmaja N (2009)                Asian            Coronary stenosis       Hospital     Retrospective   YES       RFLP         504        338
  Ghatreh Samani K et al (2009)   Middle Eastern   Coronary stenosis       Hospital     Retrospective   YES       RFLP         187        136
  Wang J (2013)                   Asian            Coronary stenosis       Hospital     Retrospective   YES       Non-RFLP     420        424
  Lu Y (Chinese) (2013)           Asian            Coronary stenosis       Population   Retrospective   NR        RFLP         442        383
  Lu Y (Malays) (2013)            Asian            Coronary stenosis       Population   Retrospective   NR        RFLP         110        155
  Lu Y (Indian) (2013)            Asian            Coronary stenosis       Population   Retrospective   NR        RFLP         110        389

Notes: CHD, coronary heart disease; NR, not reported; RFLP, restriction fragment length polymorphism; BMI, body mass index; TG, triglycerides; TC, total cholesterol; HDL-C and LDL-C, high- and low-density lipoprotein cholesterol; CETP, cholesteryl ester transfer protein; Apo-AI, apolipoprotein AI; Apo-B, apolipoprotein B.

###### The demographic characteristics of all study populations for the genotype-disease association

  Age (years)   Gender   BMI (kg/m2)   Smoking   Dyslipidemia   Hypertension   Diabetes                                                   
  ------------- -------- ------------- --------- -------------- -------------- ---------- ------- ------- ------- ------- ------- ------- -------
  71.0          76.0     1.000         1.000     27.30          26.00          NR         NR      NR      NR      NR      NR      NR      NR
  56.9          56.7     1.000         1.000     26.00          25.60          0.530      0.550   NR      NR      NR      NR      NR      NR
  61.9          58.6     0.680         0.620     25.90          25.70          0.402      0.170   NR      NR      0.310   0.168   0.087   0.020
  55.4          54.8     0.675         0.675     25.92          23.89          0.680      0.411   NR      NR      0.552   0.167   NR      NR
  58.3          58.4     1.000         1.000     25.50          25.00          0.571      0.566   0.132   0.083   NR      NR      0.056   0.027
  58.3          58.4     1.000         1.000     25.50          25.00          0.571      0.566   0.132   0.083   NR      NR      0.056   0.027
  44.0          42.2     1.000         1.000     29.00          26.60          0.468      0.203   0.449   0.250   0.375   0.172   0.108   0.020
  50.5          49.5     0.000         0.000     29.70          26.90          0.537      0.128   0.420   0.282   0.450   0.239   0.220   0.048
  54.0          52.0     0.780         0.483     32.00          25.00          0.558      0.225   NR      NR      0.467   0.108   NR      NR
  47.5          47.0     0.838         0.760     28.18          23.53          0.351      0.200   NR      NR      NR      NR      NR      NR
  50.7          49.7     0.909         0.888     24.08          23.61          0.423      0.257   NR      NR      0.381   0.305   0.337   NR
  54.6          52.8     NR            NR        27.10          26.90          NR         NR      NR      NR      NR      NR      NR      NR
  66.0          66.0     0.398         0.396     24.30          24.20          0.510      0.323   NR      NR      0.488   0.387   0.210   0.120
  59.3          42.7     0.781         0.539     24.24          23.00          0.529      0.174   0.326   0.463   0.691   0.082   0.433   0.027
  59.1          40.7     0.761         0.913     26.14          25.17          0.490      0.527   0.275   0.564   0.727   0.041   0.626   0.034
  60.4          42.4     0.835         0.622     24.90          24.77          0.438      0.136   0.211   0.643   0.618   0.098   0.618   0.064

###### The circulating lipid profiles of all study populations for the genotype-disease association

  TG (mg/dL)   TC (mg/dL)   HDL-C (mg/dL)   LDL-C (mg/dL)   CETP (μg/mL)   Apo-AI (mg/dL)   Apo-B (mg/dL)                                                     
  ------------ ------------ --------------- --------------- -------------- ---------------- --------------- -------- ------ ------ -------- -------- -------- --------
  101.86       94.77        232.02          228.15          44.08          43.70            NR              NR       NR     NR     NR       NR       NR       NR
  173.61       162.98       273.78          271.46          41.38          44.08            194.12          191.42   NR     NR     NR       NR       NR       NR
  NR           NR           NR              NR              NR             NR               NR              NR       NR     NR     NR       NR       NR       NR
  142.60       120.46       193.74          189.48          45.24          50.66            95.13           84.69    NR     NR     119.00   125.00   111.00   107.00
  NR           NR           NR              NR              NR             NR               NR              NR       NR     NR     NR       NR       NR       NR
  NR           NR           NR              NR              NR             NR               NR              NR       NR     NR     NR       NR       NR       NR
  247.40       197.50       NR              NR              38.20          43.30            NR              NR       NR     NR     NR       NR       NR       NR
  217.90       160.50       NR              NR              47.40          59.40            NR              NR       NR     NR     NR       NR       NR       NR
  164.00       136.00       201.00          204.00          38.00          47.00            131.00          129.00   NR     NR     NR       NR       NR       NR
  189.25       138.81       203.55          147.22          35.51          41.15            130.18          78.31    NR     NR     NR       NR       NR       NR
  147.10       120.30       195.70          169.04          40.90          40.62            122.90          115.92   NR     NR     NR       NR       NR       NR
  190.90       184.90       176.60          172.60          36.70          38.90            101.60          96.70    1.98   2.31   120.50   125.90   104.30   102.70
  NR           NR           182.52          158.16          46.40          47.56            109.44          94.74    NR     NR     NR       NR       NR       NR
  121.35       162.98       176.72          224.67          37.51          54.14            107.50          138.05   NR     NR     119.47   144.40   89.78    106.20
  133.75       185.12       177.88          226.22          35.19          46.02            111.76          143.08   NR     NR     115.29   129.29   103.64   121.36
  114.26       170.95       164.35          216.94          34.03          42.92            99.77           139.99   NR     NR     110.01   135.85   102.30   122.87

CHD patients were slightly older than controls (mean age: 56.74 vs. 52.99 years, *P* = 0.053) and gender composition was comparable (*P* = 0.111). Mean levels of BMI (*P* = 0.005), smoking status (*P* \< 0.001), hypertension (*P* = 0.001) and diabetes (*P* = 0.182) were significantly higher in CHD patients than in controls. By contrast, controls had significant higher levels of circulating HDL-C (*P* = 0.001) and Apo-AI (*P* = 0.026) than patients.

For the genotype-phenotype relationship, circulating HDL-C was investigated in 16 study groups and triglycerides in 9 groups, LDL-C in 9 groups, CETP in 4 groups, Apo-AI and Apo-B respectively in 3 groups, as shown in [Supplementary Table S1](#SD2){ref-type="supplementary-material"}.

CETP C-629A polymorphism and CHD risk {#s2_3}
-------------------------------------

Table [2](#T2){ref-type="table"} shows the overall and subgroup analyses of *CETP* C-629A polymorphism in association with CHD risk. In overall analyses, the -629C allele was nonsignificantly associated with a 4% (95% CI: 0.95 to 1.15; *P* = 0.412), 15% (95% CI: 0.98 to 1.35; *P* = 0.090) and 14% (95% CI: 0.99 to 1.31; *P* = 0.081) increased risk under allelic (-629C allele versus -629A allele), homozygous genotypic (-629CC genotype versus -629AA genotype) and dominant (-629CC genotype plus -629AC genotype versus -629AA genotype) models, respectively. These associations were obsessed by moderate heterogeneity, with the corresponding *I*^2^ statistic of being 69.1%, 50.2% and 60.4%. There was a low probability of publication bias except for dominant model (Egger\'s test: *P* = 0.055) (Figure [2](#F2){ref-type="fig"}). Additionally, in 5 studies involving only males, effect estimates were slightly reinforced relative to the overall estimates, and significance was detected under dominant model (OR = 1.22; 95% CI: 1.02 to 1.47; *P* = 0.033) with moderate heterogeneity (*I*^2^ = 53.0%).

###### Overall and subgroup analyses of *CETP* gene C-629A in susceptibility to CHD under three genetic models

  Groups                  Studies   Allelic model   Homozygous genotypic model   Dominant model                                                                                   
  ----------------------- --------- --------------- ---------------------------- ---------------- ------ ------ -------------- ---------- ------ ------ -------------- ---------- ------
  Overall                 16        1.04            0.95 to 1.15                 0.412            69.1   1.15   0.98 to 1.35   0.090      50.2   1.14   0.99 to 1.31   0.081      60.4
  Males only              5         1.09            0.97 to 1.21                 0.153            55.2   1.19   0.94 to 1.50   0.156      57.8   1.22   1.02 to 1.47   0.033      53.0
  Ethnicity                                                                                                                                                                       
  Asian                   7         0.96            0.78 to 1.18                 0.707            78.1   1.00   0.74 to 1.34   0.976      53.5   1.04   0.82 to 1.32   0.753      54.4
  Caucasian               3         1.18            1.08 to 1.30                 \< 0.001         0.0    1.43   1.18 to 1.74   \< 0.001   0.0    1.41   1.20 to 1.66   \< 0.001   0.0
  Mixed                   4         1.08            0.92 to 1.27                 0.363            67.8   1.17   0.83 to 1.64   0.374      68.6   1.21   0.93 to 1.56   0.153      64.8
  Middle Eastern          2         0.89            0.55 to 1.44                 0.644            73.2   0.96   0.52 to 1.78   0.901      34.2   0.79   0.40 to 1.52   0.474      72.1
  CHD subtypes                                                                                                                                                                    
  Coronary stenosis       9         0.95            0.79 to 1.14                 0.562            75.2   1.00   0.77 to 1.28   0.976      45.0   0.97   0.76 to 1.22   0.776      61.7
  Myocardial infarction   7         1.23            1.02 to 1.24                 0.015            50.9   1.28   1.05 to 1.56   0.015      52.9   1.29   1.11 to 1.51   0.001      47.8
  Source of controls                                                                                                                                                              
  Hospital                6         1.09            0.94 to 1.26                 0.267            55.1   1.27   1.04 to 1.54   0.017      3.5    1.13   0.87 to 1.48   0.363      68.5
  Population              10        1.02            0.89 to 1.16                 0.790            75.1   1.10   0.88 to 1.37   0.413      62.6   1.13   0.95 to 1.35   0.166      58.5
  Study design                                                                                                                                                                    
  Retrospective           12        1.00            0.87 to 1.15                 0.970            73.6   1.07   0.86 to 1.33   0.540      52.8   1.05   0.87 to 1.28   0.599      63.9
  Prospective             4         1.21            1.01 to 1.25                 0.038            46.9   1.27   1.02 to 1.59   0.037      49.7   1.28   1.07 to 1.54   0.007      47.3
  Matched status                                                                                                                                                                  
  YES                     11        1.01            0.88 to 1.16                 0.880            76.4   1.11   0.90 to 1.37   0.331      57.8   1.11   0.93 to 1.33   0.241      64.8
  NR                      5         1.11            0.99 to 1.24                 0.072            25.0   1.23   0.96 to 1.57   0.104      32.3   1.17   0.91 to 1.52   0.220      57.8
  Sample size                                                                                                                                                                     
  \< 500 subjects         6         0.85            0.65 to 1.12                 0.251            7.9    0.85   0.58 to 1.24   0.407      44.2   0.84   0.62 to 1.15   0.285      48.2
  ≥ 500 subjects          10        1.12            1.04 to 1.21                 0.004            46.2   1.25   1.07 to 1.46   0.005      44.0   1.25   1.09 to 1.43   0.001      51.8

Notes: OR, odds ratio; 95% CI, 95% confidence interval; NR, not reported.

![The Begg\'s funnel plots for the association of CETP C-629A polymorphism with CHD risk under three genetic models\
Each hollow circle in Begg\'s funnel plots denotes each study, and the size of circle is positively proportional to the sample size of each study.](oncotarget-08-2153-g002){#F2}

Stratifying study groups by ethnicity identified significance only in Caucasians, with the odds of CHD being 1.18, 1.43 and 1.41 respectively under allelic, homozygous genotypic and dominant models (*P* \< 0.001 for all), without observable heterogeneity (*I*^2^ = 0% for all). In contrast, the effect estimates were in an opposite direction, albeit nonsignificant in Middle Easterns across three genetic models.

In subgroup analyses by CHD subtypes, the -629C allele was observed to significantly increase risk of myocardial infarction by 1.23-, 1.28- and 1.29-fold respectively under allelic (*P* = 0.015), homozygous genotypic (*P* = 0.015) and dominant (*P* = 0.001) models, with borderline heterogeneity. By source of controls, the effect estimates were roughly comparable between hospital- and population-based studies, with significant heterogeneity.

By study design, the -629C allele seemed to confer a 21% to 28% increased risk for CHD in prospective studies across three genetic models (*P* \< 0.05) without evident heterogeneity, while this risk was reduced towards the unity in retrospective studies.

When the analysis was restricted to the large study (≥ 500 subjects), pooled risk estimates were statistically significant under allelic (OR = 1.12; *P* = 0.004), homozygous genotypic (OR = 1.25; *P* = 0.005) and dominant (OR = 1.25; *P* = 0.001) models with borderline heterogeneity, while an opposite yet nonsignificant association was identified in the small studies (\< 500 subjects).

CETP C-629A polymorphism and lipid changes {#s2_4}
------------------------------------------

Table [3](#T3){ref-type="table"} presents the overall analyses of *CETP* C-629A polymorphism with circulating lipid changes under both homozygous genotypic and dominant models. An increase in circulating CETP was observed for carriers of the -629CC genotype (WMD: 0.70 μg/mL; 95% CI: 0.30 to 1.10; *P* = 0.001) or -629C allele (WMD: 0.45 μg/mL; 95% CI: 0.25 to 0.65; *P* \< 0.001) relative to the -629AA homozygotes, with evident heterogeneity. By contrast, there was a reduced yet nonsignificant trend in circulating triglycerides for -629CC genotype or -629C allele carriers, and the probabilities of heterogeneity and publication bias were low.

###### Overall analyses of *CETP* gene C-629A with circulating lipids under both genotypic and dominant models

  Lipids          Genetic models   Studies     WMD                  95% CI               *P*         *I*^2^ (%)
  --------------- ---------------- ----------- -------------------- -------------------- ----------- ------------
  CETP            Genotypic        4           **0.70**             **0.30 to 1.10**     **0.001**   83.1
  Dominant        4                **0.45**    **0.25 to 0.65**     **\< 0.001**         69.3        
  Triglycerides   Genotypic        9           −2.11                −13.30 to 9.07       0.711       12.9
  Dominant        9                −0.77       −12.41 to 10.86      0.896                42.3        
  HDL-C           Genotypic        16          **−4.36**            **−7.20 to −1.51**   **0.003**   84.2
  Dominant        16               **−3.65**   **−5.59 to −1.70**   **\< 0.001**         78.7        
  LDL-C           Genotypic        9           9.60                 −0.60 to 19.80       0.065       74.8
  Dominant        9                7.03        −0.62 to 14.67       0.072                69.6        
  Apo-AI          Genotypic        3           −0.75                −6.60 to 5.10        0.800       0.0
  Dominant        3                −3.66       −7.76 to 0.43        0.079                0.0         
  Apo-B           Genotypic        3           4.77                 −3.34 to 12.87       0.249       0.0
  Dominant        3                4.91        −1.10 to 10.91       0.109                0.0         

Notes: WMD, weighted mean difference; 95% CI, 95% confidence interval.

Circulating HDL-C was significantly reduced in carriers of the -629CC genotype (WMD: -4.36 mg/dL; 95% CI: -7.20 to -1.51; *P* = 0.003) or -629C allele (WMD: −3.65 mg/dL; 95% CI: -5.59 to -1.70; *P* \< 0.001) when compared with the -629AA homozygotes, with moderate heterogeneity and a low probability of publication bias. The -629CC genotype or -629C allele was associated with higher circulating LDL-C than the -629AA genotype, while no significance was reached. Similarly, the -629CC genotype or -629C allele was associated with lower Apo-AI but higher Apo-B than the -629AA genotype, with no observable heterogeneity.

Meta-regression analyses {#s2_5}
------------------------

To further seek possible causes of clinical heterogeneity, meta-regression analyses that modeled age, male gender, BMI, smoking, dyslipidemia, hypertension, diabetes, circulating triglycerides, total cholesterol, HDL-C, LDL-C, CETP, Apo-AI and Apo-B if available under study were conducted, and none of these factors contributed significantly to the association of *CETP* C-629A polymorphism with CHD risk (all *P* \> 0.05).

Cumulative and influential analyses {#s2_6}
-----------------------------------

Cumulative analyses by ascending publication years indicated no substantive change in the direction of effect estimates with the addition of subsequent studies ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}). In addition, influential analyses confirmed the stability of overall effect estimates ([Supplementary Figure S2](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

The objective of this meta-analysis was to evaluate the association of *CETP* C-629A polymorphism with the risk of CHD and lipid changes by summarizing data from 17 articles. The key finding of this study was that the -629C allele was significantly associated with an increased risk of CHD in Caucasians, and this association may be mediated by its phenotypic regulation on circulating CETP and HDL-C. The importance of the current study lies in deepening our understanding of the functional aspects of *CETP* genetic variation involved in the pathogenesis of CHD.

Lately, a large comprehensive meta-analysis choosing *CETP* gene TaqIB (rs708272) polymorphism as an instrument has demonstrated that circulating CETP may play a causal role in the pathophysiology of CHD \[[@R25]\], although there are still some unresolved issues revolving around the prerequisites of Mendelian randomization analysis \[[@R26]\], such as pleiotropic impact of genetic polymorphism under study and linkage disequilibrium with another locus that differently modifies circulating CETP. Nevertheless, it still remains an open question to interrogate *CETP* genetic loci associated with CHD risk and responsible for the changes of biologically relevant lipids. The conduct of this meta-analysis therefore represents a supplement to medical research and deepens our understanding of the genetics of CHD.

As indicated in this meta-analysis, *CETP* C-629A mutation can alter susceptibility to CHD in Caucasian populations, at least in part, through its phenotypic regulation on circulating CETP and HDL-C. Several cautionary notes regarding the interpretation and extrapolation of this finding should be sounded. First, genetic heterogeneity across ethnicities is a common phenomenon gripping a majority of association studies. It is of interest to found that *CETP* -629C allele was significantly associated with an increased risk of CHD only in Caucasians, while this association was reversed to be protective in Asian and Middle Eastern populations. As a matter of fact, linkage disequilibrium patterns are generally believed to be diverse across races or ethnicities. For example, the linkage of a genetic variant with another functional variant was usually strong in one ethnic group but weak or nonexistent in another \[[@R27]\]. Second, experimental data suggested the close association of *CETP* genetic alterations with increased large cholesterol-enriched HDL particles \[[@R28]\]. Moreover, the fact that simple measurement of circulating HDL-C may not always reflect the potential cardioprotective activity of HDL particle, which might be dysfunctional in spite of high HDL-C can by no means be ignored \[[@R29]\]. It is widely recognized that cholesterol-overloaded HDL particle can not only decrease the hepatic selective uptake of cholesterol from HDL particle, but also exert a defective effect on efflux potential of cholesterol from extra-hepatic cells \[[@R30]--[@R32]\]. In addition, some pharmacological agents such as CETP inhibitors \[[@R33]\] and Niacin \[[@R34]\] that raise circulating HDL-C simultaneously increased the levels of cholesterol-overloaded particles. Third, the association of *CETP* C-629A polymorphism with CHD risk had a biological basis, as this polymorphism also accounted for the changes of circulating CETP concentrations. In addition, this association was strengthened after restricting analysis to the prospective and large studies, which further verifies the robustness of our meta-analytic findings.

A number of possible limitations should be recognized for this meta-analysis. First, only summary data from published papers were abstracted, and it could yield further insights if individual participant data were analyzed. Second, we were unable to glean various potential confounders (smoking, dyslipidemia, hypertension and diabetes) from all eligible studies, and only five studies provided complete confounding data. We adopted meta-regression analyses in an attempt to account for this limitation, while no significance was identified. Third, only one promoter polymorphism, C-629A in *CETP* was meta-analyzed, which is clearly not sufficient to support the contributory role of *CETP* in the pathogenesis of CHD and lipid regulation, as other polymorphisms in or flanking CETP might synergize or antagonize the impact of C-629A. Fourth, the association of *CETP* C-629A polymorphism with CHD risk and circulating lipid changes is not based on the same dataset due to limited number of qualified studies. Fifth, as with most meta-analyses, publication bias might be possible because only published articles were retrieved and the 'grey' literature (articles in languages other than English) was not reviewed. In view of these limitations, the jury must refrain from jumping at a conclusion until further verification of our findings in large, long-term, well-designed prospective studies.

Taken together, our meta-analytic findings demonstrate that the -629C allele was significantly associated with an increased risk of CHD in Caucasians, and this association may be mediated by its phenotypic regulation on circulating CETP and HDL-C. Although further investigations are required to elucidate the molecular mechanisms of *CETP* C-629A polymorphism underlying CHD, future studies on the relationship between *CETP* genetic defects and CHD susceptibility need to focus on gene-to-environment interactions, especially on the impact of the -629C allele on circulating lipid changes.

MATERIALS AND METHODS {#s4}
=====================

This meta-analysis of observational studies was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) statement \[[@R35]\]. All observational studies included were reported to obtain ethical approvals from the Ethics Committees of local institutions or departments.

Search strategy {#s4_1}
---------------

PubMed/Medline, Embase, Scopus and Google Scholar electronic resources were searched on July 21, 2016 to seek articles of potential relevance, by using subject headings ('cholesteryl ester transfer protein' or 'cholesterol ester transfer protein' or 'CETP' and 'coronary heart disease' or 'isch\[a\]emic heart disease' or 'myocardial infarction' or 'atherosclerosis' or 'arteriosclerosis' or 'coronary artery disease' or 'coronary disease') and ('polymorphism' or 'variant' or 'variation' or 'mutation' or 'SNP'). The bibliographies of retrieved articles were also reviewed for articles that might be missed.

Eligibility assessment {#s4_2}
----------------------

The eligibility of each article was justified by two investigators (Shouwei Lin and Rong Lin) by reading the title and abstract, and if necessary the full text. Meanwhile, the period and location, if available, for study subjects collected were recorded to judge whether there were multiple publications from the same study. If so, the publication with a larger sample size was retained.

To be more specific, three inclusion criteria were proposed: (1) only English-language publications were considered; (2) the association of *CETP* C-629A polymorphism with CHD risk or circulating lipid changes was evaluated; (3) the absolute counts of C-629A genotypes between CHD patients and controls or the circulating lipid concentrations across C-629A genotypes were provided. In addition, articles were not taken into account if they were conference abstracts/posters, case reports, editorials and narrative/systematic reviews.

Data extraction {#s4_3}
---------------

The same two investigators (Shouwei Lin and Rong Lin) independently extracted data from each qualified article according to a jointly formulated protocol, including first author\'s surname, publication year, ethnicity, diagnostic criteria of CHD including coronary stenosis or myocardial infarction, study design (retrospective or prospective design), source of controls (hospitals or populations), matched situation, sample size, absolute genotype counts of *CETP* C-629A polymorphism between CHD patients and controls or mean (standard deviation) concentrations of circulating CETP, triglycerides, HDL-C, LDL-C, Apo-AI and Apo-B across C-629A genotypes, as well as age, male gender, body mass index (BMI), smoking, dyslipidemia, hypertension, diabetes, circulating triglycerides, total cholesterol, HDL-C, LDL-C, CETP, Apo-AI and Apo-B, if available, between CHD patients and controls. For the sake of consistency, circulating triglycerides, total cholesterol, HDL-C, LDL-C, Apo-AI and Apo-B were expressed in mg/dL and CETP in μg/mL.

Statistical analysis {#s4_4}
--------------------

Unadjusted odds ratio (OR) and weighted mean difference (WMD), along with 95% confidence interval (95% CI) were calculated by using a random-effects model with the DerSimonian & Laird method to pool individual effect-size estimates under all circumstances. The magnitude of statistical heterogeneity across studies was represented by the inconsistency index (*I*^2^) statistic (range: 0% to 100%). Statistical heterogeneity was reported to be significant if the *I*^2^ statistic is over 50%, which is a generally accepted cutoff value \[[@R36]\].

To explore the possible causes of clinical heterogeneity, grouping all qualified studies by gender, ethnicity, CHD subtype, control source, study design, matched status and sample size was conducted, separately. In addition, clinical heterogeneity was explored by meta-regression analyses that incorporated all available discrete and continuous variables under study.

To see how effect estimates have shifted over time, cumulative analyses were performed in time sequence with each sub-analysis incorporating one additional study. To examine the robustness of overall estimates, influential analyses were undertaken by excluding each study from the analysis to seek its impact on the overall findings.

The assessment of publication bias was made by the Begg\'s funnel plots and Egger\'s asymmetry tests. The Egger\'s test can inspect funnel plot asymmetry by determining whether the intercept deviates significantly from zero when regressing the standardized effect estimates against their precision \[[@R37]\]. *P* \< 0.10 was chosen for the significance of Egger\'s tests. Data were statistically analyzed by the STATA software version 14.0 for Windows 10.0 (StataCorp, College Station, TX, USA).
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